Guidelines for the management of castrate-resistant prostate cancer

Journal of the Canadian Urological Association

Volumn 4, Issue 6, 2010, Pages 380-384

  Saad, Fred ^a   Hotte, Sebastien J ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649933390     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: 10.5489/cuaj.10167     Document Type: Article

References (34)

1. Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer, Cancer Res 2007;67:5033-41.
2. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59.
3. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583), J Clin Oncol 2004;22:1025-33.
4. Storlie JA, Buckner JC, Wiseman GA, et al. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma, Cancer 1995;76:96-100.
5. Heng DY, Chi KN. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer. Can J Urol 2006;13:3335-9.
6. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
7. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
8. Winquist E, Waldron T, Berry S, et al. Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidencebased Care's Genitourinary Cancer Disease Site Group. BMC Cancer 2006;6:112-130.
9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Fort Washington, PA: NCCN, 2010. www.nccn.org/professionals/physician_gls/PDF/prostate.pdf. Accessed October 18, 2010.
10. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints, J Clin Oncol 1996;14:1756-64.
11. Michels J, Montemurro T, Murray N, et al. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer 2006;106:1041-6.
12. Oh WK, Manola J, Babcic V, et al. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 2006;67:1235-40.
13. Berthold DR, Pond G, De Wit R, et al. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008;19:1749-53.
14. Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007;110:556-63.
15. Berger ER, Ciuleanu T, Hart L, et al. Results of a randomized phase II study of irofulven in hormonerefractory prostate cancer patients that have failed first-line docetaxel treatment [abstract 5068]. J Clin Oncol 2007;25(18S).
16. Beer TM, Ryan CW, Venner PM, et al. Intermittent chemotherapy in patients with metastatic androgenindependent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 2008;112:326-30.
17. Jankovic B, Beardsley E, Chi KN. Rechallenge with docetaxel as second-line chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) after previous docetaxel: a population based analysis [abstract 196]. In: 2008 ASCO Genitourinary Symposium; February 14-16, 2008; San Francisco, CA.
18. Ansari J, Hussain SA, Zarkar A, et al. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. Oncol Rep 2008;891-6.
19. Eymard J, Oudard S, Gravis G, et al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int Epub 2010 Mar 9.
20. Sartor AO, Oudard S, Ozguroglu M, et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC) [abstract 9]. Presented at: 2010 ASCO Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, CA.
21. Wu JS, Wong RK, Lloyd NS, et al. Radiotherapy fractionation for the palliation of uncomplicated painful bone metastases - an evidence-based practice guideline. BMC Cancer 2004;4:71.
22. Diamond TH, Higano CS, Smith MR, et al. Osteoporosis in men with prostate carcinoma receiving androgendeprivation therapy: recommendations for diagnosis and therapies. Cancer 2004;100:892-9.
23. Preston DM, Torrens JI, Harding P, et al. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Prostate Cancer Prostatic Dis 2002;5:304-10.
24. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer, N Engl J Med 2005;352:154-64.
25. Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579-84.
26. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82.
27. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Annals Oncol 2008;19:420-32.
28. Sarin J, DeRossi SS, Akintoye SO. Updates on bisphosphonates and potential pathobiology of bisphosphonate- induced jaw osteonecrosis. Oral Dis 2008;14:277-85.
29. Pazianas M, Miller P, Blumentals WA, et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007; 29:1548-58.
30. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7:508-14.
31. Ullen A, Lennartsson L, Harmenberg U, et al. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 2005;44:644-50.
32. Saad F, Markus R, Goessl C. Targeting the receptor activator of nuclear factor-kB (RANK) ligand in prostate cancer bone metastases. BJU Int 2007;101:1071-5.
33. Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745-55.
34. Fizazi K, Carducci M, Smith M, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with castration resistant prostate cancer [abstract LBA4507]. J Clin Oncol 2010;28:18s.